Cerebellar grey-matter deficits, cannabis use and first-episode schizophrenia in adolescents and young adults by Cohen, Martin et al.
Cerebellar grey-matter deﬁcits, cannabis use
and ﬁrst-episode schizophrenia in adolescents
and young adults
Martin Cohen1,2,3*, Paul E. Rasser1,2,3*, Greg Peck2, Vaughan J. Carr1,4, Philip B. Ward4,
Paul M. Thompson5, Patrick Johnston6, Amanda Baker1,2,3 and Ulrich Schall1,2,3
1 Schizophrenia Research Institute, Sydney, Australia
2 Priority Centre for Brain & Mental Health Research, The University of Newcastle, Australia
3 Hunter Medical Research Institute, Newcastle, Australia
4 School of Psychiatry, University of New South Wales, Sydney, Australia
5 Laboratory of Neuro Imaging, University of California Los Angeles, CA, USA
6 Department of Psychology, University of York, UK
Abstract
Epidemiological data link adolescent cannabis use to psychosis and schizophrenia, but its contribution to
schizophrenia neuropathology remains controversial. First-episode schizophrenia (FES) patients show
regional cerebral grey- and white-matter changes as well as a distinct pattern of regional grey-matter loss
in the vermis of the cerebellum. The cerebellum possesses a high density of cannabinoid type 1 receptors
involved in the neuronal diversiﬁcation of the developing brain. Cannabis abuse may interfere with this
process during adolescent brain maturation leading to ‘schizophrenia-like’ cerebellar pathology.
Magnetic resonance imaging and cortical pattern matching techniques were used to investigate cerebellar
grey and white matter in FES patients with and without a history of cannabis use and non-psychiatric
cannabis users. In the latter group we found lifetime dose-dependent regional reduction of grey matter in
the right cerebellar lobules and a tendency for more profound grey-matter reduction in lobule III with
younger age at onset of cannabis use. The overall regional grey-matter diﬀerences in cannabis users were
within the normal variability of grey-matter distribution. By contrast, FES subjects had lower total
cerebellar grey-matter : total cerebellar volume ratio andmarked grey-matter loss in the vermis, pedunculi,
ﬂocculi and lobules compared to pair-wise matched healthy control subjects. This pattern and degree of
grey-matter loss did not diﬀer from age-matched FES subjects with comorbid cannabis use. Our ﬁndings
indicate small dose-dependent eﬀects of juvenile cannabis use on cerebellar neuropathology but no
evidence of an additional eﬀect of cannabis use on FES cerebellar grey-matter pathology.
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Introduction
Cannabis is the most commonly used illicit drug,
abused by approximately 4% of the adult population
worldwide (United Nations Oﬃce on Drugs and
Crime, 2008). Particularly high rates are recorded
for North America and Oceania. Approximately 40%
of the North American population aged o12 yr (Sub-
stance Abuse and Mental Health Services Adminis-
tration, 2009) and 34% of the Australian population
aged o14 yr (Australian Institute of Health and
Welfare, 2008) had a reported lifetime use of cannabis.
The European Union recorded lower rates at 22% for
the 15–64 yr age group (Vicente et al. 2008). Of par-
ticular concern is the increasing trend for using hydro-
ponically grown cannabis with signiﬁcantly higher
tetrahydrocannabinol (THC) content at younger ages
(see review by Copeland & Swift, 2009).
Meta-analyses by Moore and colleagues (2007)
show that there is an increased risk of psychosis
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(i.e. beyond the immediate impact of intoxication) in
individuals who had ever used cannabis and a greater
risk in people who have used cannabis more fre-
quently. Although the authors concluded that an as-
sociation with mood and aﬀective disorders was less
clear, the observation of increased risk of psychosis
raises health concerns for the mental wellbeing of
young regular users of cannabis.
Cannabis is a plant derivative of Cannabis sativa,
C. indica, and C. ruderalis which diﬀer in their respect-
ive THC and cannabidiol content. THC is the
main psychoactive compound and acts on the CB1
cannabinoid receptor in the nervous system. In the
human brain, the highest density of CB1 receptors
is found in the midbrain (i.e. substantia nigra, red
nucleus, central grey, and superior colliculus), fol-
lowed by the basal ganglia (i.e. globus pallidus) and
the molecular layer of the cerebellum. Lower densities
are found in layer I of the primary and secondary
visual cortex (Glass et al. 1997).
In the adult brain, endocannabinoids (e.g.
anandamide and 2-arachnidonoylglycerol) mediate
retrograde synaptic signalling, thereby controlling
synaptic plasticity. CB1 receptors play an integral
role in synapto-, neuro- and morphogenesis as well as
neuronal migration and speciﬁcation during brain
development (Harkany et al. 2008). Postnatal brain
maturation is largely deﬁned by myelination and
synaptic pruning. These processes result in grey-
matter thinning and a white-matter volume increase
(e.g. Gogtay & Thompson, 2010).
Of particular interest are the neurodevelopmental
processes of adolescence and early adulthood when
schizophrenia emerges and cannabis abuse is most
prevalent. The role of the endocannabinoid system in
this phase of brain maturation remains unclear, but
the continued expression of CB1 receptors in brain
regions that change during adolescence suggests an
ongoing role, e.g. in synapse formation (Harkany et al.
2008).
There is clear evidence for substantial structural
brain changes in ﬁrst-episode schizophrenia (FES),
including some evidence suggesting that these changes
already emerge in the prodromal phase of illness (e.g.
Borgwardt et al. 2007; Lappin et al. 2007; Takahashi
et al. 2009; Witthaus et al. 2009). Rais and colleagues
further reported that FES patients who have used
cannabis show a more pronounced brain volume re-
duction over a 5-yr period than patients with schizo-
phrenia who did not use cannabis (Rais et al. 2008).
While these authors did not report cerebellum data,
cerebellar atrophy has been detected in individuals
followed longitudinally from the prodromal phase of
the illness (Borgwardt et al. 2008; Pantelis et al. 2003).
Progression of vermal atrophy in childhood-onset
schizophrenia patients has not been conﬁrmed by re-
peated magnetic resonance imaging (MRI) (Keller et al.
2003). Together, these ﬁndings support the notion
of cerebellar neuropathology in schizophrenia that is
already present in the emerging phase of illness. We
investigated whether a history of juvenile cannabis
consumption in the prodromal phase of illness was
also associated with more pronounced cerebellar
neuropathology in FES as reported for the cerebrum
(Rais et al. 2008).
Cannabis-induced brain changes in otherwise
healthy individuals are comparatively less prominent
(for review see Martı´n-Santos et al. 2010). Reported
cannabis-induced brain changes range from altered
gyriﬁcation in young users, consistent with neuro-
developmental abnormalities (Mata et al. 2010), to
volumetric reductions of amygdala and hippocampus
in an exposure-dependent fashion (Yucel et al. 2008).
In the latter study, sub-threshold positive symptoms
were also correlated with left-hemispheric hippo-
campal volume reduction and cumulative lifetime ex-
posure to cannabis. Compared to studies of structural
brain changes, functional brain-imaging studies are
more common. These predominantly show reduced
prefrontal blood ﬂow in cannabis users compared to
non-users (for review see Martı´n-Santos et al. 2010).
However, there are very few studies speciﬁcally in-
vestigating eﬀects of juvenile cannabis use on the cer-
ebellum. For instance, Medina et al. (2010) reported
larger vermal volumes in recently abstinent cannabis
users, along with impaired executive functions, which
is in contrast to the ﬁndings reported for the cerebrum
showing smaller regional volumes with cannabis use
in a dose-dependent fashion (e.g. Yucel et al. 2008).
Here we report on the neurodevelopmental eﬀects
of juvenile cannabis use on the CB1-rich grey matter of
the cerebellum (Glass et al. 1997) in a group of young
people with heavy cannabis abuse during adolescence.
We hypothesized that cerebellar grey-matter reduc-
tion would be related to : (1) age at onset of cannabis
use (i.e. greater reduction when use starts at a younger
age) ; (2) duration of cannabis use (i.e. more grey-
matter reduction with longer use) ; and (3) the total
amount of accumulated lifetime dose (i.e. dose-
dependent reduction of grey matter).
We also examined the eﬀect of cannabis use on
cerebellar pathology in young people diagnosed with
FES (e.g. Okugawa et al. 2007; Thomann et al. 2009;
Whitford et al. 2006). We hypothesized that (4) FES
cannabis users would show greater regional grey-
matter reduction in the cerebellum compared to a
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group of non-using FES, and that (5) cannabis use
contributes to and overlaps with the cerebellar grey-
matter reduction pattern found in non-using FES. The
latter hypothesis reﬂects the notion of a promoting
eﬀect of juvenile cannabis use on cerebellar pathology
as, for instance, Bangalore et al. (2008) reported as de-
creased grey-matter density in the CB1 receptor-
rich region of right posterior cingulate cortex when
employing a voxel-based morphometric analysis
and comparing cannabis-using with non-using FES
patients.
Methods
Ethics approval for this study was granted by the
human research ethics committees of the Universities
of Newcastle and New South Wales, Hunter New
England Health, and South Eastern Sydney Area
Health. Participants gave written informed consent.
Subjects
Nineteen healthy non-drug-using volunteers, 17
young cannabis users, 13 non-using and six cannabis-
using FES outpatients were recruited through com-
munity advertisement. FES patients had a history
of<5 yr since their ﬁrst psychotic episode and<2 yr
since meeting DSM-IV criteria for schizophrenia (First
et al. 1997). All four participant groups were closely
matched for age, gender and handedness as well as for
cannabis-use history (for the cannabis-using subjects)
and duration of illness (for the FES subjects ; Table 1).
FES participants were in remission after no more
than one hospital admission and were maintained on
atypical antipsychotic monotherapy (i.e. risperidone,
olanzapine, aripiprazole, quetiapine) when recruited
into the study.
The Opiate Treatment Index (Darke et al. 1991)
was used to assess illicit and licensed drug use and to
estimate the quantity/frequency of cannabis use ex-
pressed as individual consumption events and referred
to as ‘doses’ (Darke et al. 1991; Table 1). All partici-
pants were right-handed (Edinburgh Handedness
Scale ; Oldﬁeld, 1971). Exclusion criteria for all par-
ticipants included non-cannabis forms of substance
abuse or dependence, other than caﬀeine or nicotine
according to DSM-IV criteria. As a result, the groups
did not diﬀer on any substance use patterns other
than cannabis (Table 1). Other exclusion criteria in-
cluded: a history of signiﬁcant head injury, relevant
neurological (e.g. epilepsy) or medical (e.g. endocrine)
conditions, ferromagnetic implants, claustrophobia
or other anxiety disorders, failure to complete at
least 3 yr of secondary school, or National Adult
Reading Test (Nelson & Willison, 1991) IQ estimates
of<70.
Magnetic resonance data acquisition and processing
MRI data were acquired using a Siemens Magnetom
Vision 1.5 T MRI scanner (John Hunter Hospital,
Newcastle, Australia). High-resolution structural
brain MR data were collected from each subject with
approximate dimensions of 164r256r256 with each
voxel being 1r1r1 mm. We used a 3D MPRAGE
(magnetization prepared gradient echo) protocol with
repetition time (TR)=9.7 ms, echo time (TE)=4 ms,
and ﬂip angle=12x.
Table 1. Demographic, handedness, age at psychosis onset, cannabis, alcohol and tobacco use data [standard deviations
(S.D.) given in parentheses] for healthy control subjects, cannabis-using subjects, ﬁrst-episode schizophrenia (FES) subjects, and
cannabis-using FES subjects
Control
subjects
Cannabis-using
subjects FES
Cannabis-using
FES p
Male/female 15/4 15/2 12/1 4/2 0.64a
Age, yr (S.D.) 21.5 (2.3) 22.7 (2.4) 20.7 (3.6) 21.8 (1.9) 0.24b
Handedness (R/L) 19/0 17/0 13/0 6/0 –
Age at ﬁrst psychotic episode, yr (S.D.) – – 17.5 (2.5) 17.4 (2.2) 0.96b
Age, yr, at onset of THC use (S.D.) – 15.1 (2.4) – 15.5 (2.3) 0.74b
Years of THC use (S.D.) – 7.6 (2.6) – 6.3 (2.3) 0.30b
Estimated total lifetime THC doses (S.D.) – 22 700 (16 400) – 17 900 (19 000) 0.56b
Estimated alcohol consumption, grams/day (S.D.) 11.2 (14.5) 24.1 (24.0) 18.0 (6.0) 29.7 (27.2) 0.09b
Daily tobacco consumption (Y/N) 7/12 13/4 5/8 3/6 0.14a
a x2 test (Yates-corrected).
b One-way ANOVA.
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Pre-processing of the subject’s MRI scan followed
a protocol (Rasser et al. 2010) involving trans-
formation to ICBM space (Mazziotta et al. 2001), radio-
frequency bias correction (Sled et al. 1998), manual
delineation of the cerebellum (blind to diagnosis) fol-
lowed by the extraction of a surface-based model
of the cerebellar cortex (MacDonald et al. 1994). Using
the surface model and all three triaxial sections of
the subject’s MRI, ﬁve cerebellar ﬁssures (intra-
culminate, primary, superior posterior, horizontal,
secondary) were identiﬁed and traced onto their
cerebellar model (Fig. 1a). A cortical pattern-matching
technique (Rasser et al. 2010; Thompson et al. 2004)
was then employed to deform each subject’s cerebellar
model to a geometrically averaged target set of
ﬁssures.
Using a dilated version of their native space
cerebellar mask, a secondary correction for radio-
frequency bias (intensity inhomogeneity) was applied
to the subject’s MRI to improve the homogeneity
of intensities within each tissue class. Each subject’s
cerebellum was then isolated using their cerebellar
mask, followed by intensity normalization, and total
cerebellar volume was calculated.
Cerebellar grey- and white-matter tissues were
classiﬁed using a thresholding procedure (Atkins &
Mackiewich, 1998). This procedure divided the tissue
classes based on a constant oﬀset from the mean of a
single ﬁtted Gaussian model for each subject. Tissue-
classiﬁed volumes were used to measure total cer-
ebellar grey- and white-matter volumes.
For the regional assessment of grey matter in
native space, the proportion of cerebellar voxels
labelled as grey matter was calculated within volume-
dependent spherical kernels with centres correspond-
ing to the vertices of the subject’s deformed cerebellar
cortex model. These spherical kernels, with radius
15 mm, were varied subject-wise by the ratio of the
individual to the average cerebellar volume, with the
average determined from a reference sample (Rasser
et al. 2010) of 18 control subjects also belonging to
this study.
A deformable cerebellar atlas (Fig.1b) (Rasser et al.
2010) was then deformed using cortical pattern-
matching to the average target atlas, enabling the
tabulation of each subject’s average proportion of grey
matter for each lobule. The deformable atlas was gen-
erated from a symmetrical version (across the central
sagittal plane) of the Montreal Neurological Institute
intensity-averaged single-subject MRI (Holmes et al.
1998). Labelling of lobule and feature boundaries of
the deformable atlas was as described in Schmahmann
et al. (2000).
Statistical analyses
Demographic data were compared between groups
by non-parametric testing (i.e. x2 statistics with Yates
correction when indicated) for nominal data or one-
way ANOVA at p<0.05 (two-sided). Data distribution
was tested prior to parametric testing. Associations
between parameters describing cannabis-use history
(i.e. age of onset and duration of cannabis use and es-
timated individual total lifetime doses) were tested
with Pearson’s correlation coeﬃcients at p<0.05 (two-
sided) in the cannabis-using group. Total cerebellar
volume, total grey- and white-matter volumes, ratios
of total grey : total cerebellar volumes, and lobule-level
group diﬀerences of grey matter were tested by one-
way ANOVA at p<0.05 (two-sided and Bonferroni-
corrected for multiple comparisons) between all four
groups (i.e. non-using healthy control subjects,
cannabis-using subjects, FES subjects, cannabis-using
FES subjects). This was followed by Scheﬀe´ ’s post-hoc
group comparisons and linear regression with the
parameters describing cannabis-use history as pre-
dictors and lobule-level grey-matter diﬀerences as the
dependent variable. The respective main eﬀects and
interaction between diagnosis of FES and cannabis use
was tested by two-way ANOVA at p<0.05 (two-sided)
across all four groups.
Parametric statistical maps of cerebellar grey-matter
measures by group (i.e. non-using healthy control
subjects, cannabis-using subjects, FES subjects,
cannabis-using FES subjects) were calculated and
permutation-tested (Thompson et al. 2003) at p<0.05
for each hemisphere. Permutation testing ascribes an
overall corrected p value to a whole map of statistics,
based on estimating the chance that the overall surface
area of suprathreshold statistics could have been ob-
tained by chance in null data, simulated by randomly
assigning patients and controls to two groups.
Results
There was mixed support for the hypotheses.
Cannabis use did not aﬀect total cerebellar volume,
white- or grey-matter volumes, nor total grey : total
cerebellar volume ratios (Table 2). Parametric map-
ping suggested some regional eﬀects of cannabis use
on grey matter depending on age at onset of use, years
of use, and accumulated total lifetime doses (Fig. 1c–e).
Permutation testing conﬁrmed signiﬁcant grey-matter
reduction for total lifetime dose for the right cerebellar
hemisphere (p=0.04, Fig. 1e).
The parameters describing cannabis use were
partially inter-correlated in the otherwise healthy
cannabis-using group. Age at onset of cannabis use
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Fig. 1. From top to bottom, superior, left, right, posterior, anterior, and inferior views of cerebellum. (a) Traced ﬁssure lines (intra-culminate, primary, superior posterior, horizontal,
secondary) for cortex model transformation (modiﬁed from Rasser et al. 2010). (b) Deformable lobule labels, enabling lobule-wise grey-matter measures for each subject (modiﬁed
from Rasser et al. 2010). Correlation maps of cerebellar grey matter with (c) age of onset of cannabis (THC) use, (d) years of use, and (e) cumulated lifetime exposure. (f) Cannabis-use
history eﬀects of juvenile THC use were statistically conﬁrmed for the right lobules III, IV, and V.
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correlated with years of use (r=x0.52, p=0.03) which,
in turn, correlated with total individual lifetime doses
(r=0.58, p=0.01). Hence, post-hoc statistical analyses at
lobule level were performed by linear regression with
age of onset, years of use, and total lifetime doses as
predictors and grey-matter measures in individual cer-
ebellar lobules and areas as deﬁned by Schmahmann
et al. (2000) as the dependent variable. Consistent with
parametric mapping (Fig. 1c–e), grey-matter reduction
was conﬁrmed for three lobules as dependent on the
three parameters describing the pattern of cannabis-
use history (lobule III : F3,16=4.4, p=0.02 ; lobule IV:
F3,16=4.7, p=0.02 ; lobule V: F3,16=4.6, p=0.02 ; Fig. 1 f)
with total lifetime doses signiﬁcantly predicting grey-
matter reduction in these lobules (lobule III : b=
x0.63, t=x2.6, p=0.02 ; lobule IV: b=x0.74, t=x3.1,
p<0.01 ; lobule V: b=x0.52, t=x2.2, p<0.05 ;
Supplementary Fig. S1, available online). Age at onset
of cannabis use also showed a statistically non-
signiﬁcant trend towards being associated with grey-
matter reduction in lobule III (b=x0.46, t=x2.0,
p<0.07 ; Supplementary Fig. S2, available online).
Parametric mapping suggested no regional diﬀer-
ences in cerebellar grey matter in cannabis users vs.
pair-wise age-, gender-, and handedness-matched
healthy control subjects (Fig. 2a). By contrast, FES
subjects showed a marked reduction of grey matter in
the superior vermis, in left lobule VI, in right-inferior
lobule IX, extending into left lobule IX, bilaterally in
the areas of lobuli III, peduncle and left ﬂocculus,
compared to pair-wise age-, gender-, and handedness-
matched healthy controls (Fig. 2b). These grey-matter
deﬁcits were conﬁrmed by permutation testing for the
left (p<0.003) and right (p<0.005) cerebellar hemi-
spheres.
Grey-matter reductions in FES were also conﬁrmed
by parametric mapping across the three groups
(i.e. healthy control, cannabis user, FES subjects) by
permutation testing for the left (p<0.002) and right
(p<0.003) cerebellar hemispheres (Fig. 2c). Moreover,
FES subjects also showed greater total white-matter
volume (p=0.03) and lower total grey : total cerebellar
volume ratio (p=0.007) than healthy controls (Table 2).
To assess the respective contributions of cannabis
use and schizophrenia to regional grey-matter changes,
all study participants were entered into a two-way
ANOVA with the independent factors of cannabis use
(yes/no) and the diagnosis of schizophrenia (yes/no).
A main eﬀect of the diagnosis of schizophrenia was
conﬁrmed for total grey: total cerebellar volume ratios
(F1,51=10.6, p=0.002 ; Supplementary Fig. S3, available
online) due to grey-matter loss on lobules III, IV, V, VI,
IX, pedunculi, ﬂocculi, and vermis (F1,51=4.5–14.3,
p<0.05–<0.001 ; Fig. 2d – light blue areas) which cor-
responds to the main eﬀect of group in lobules III,
IX, pedunculi, ﬂocculi, and vermis (F3,51=2.8–5.8,
p<0.05–0.002; Fig. 2d – dark blue areas). After cor-
recting for multiple testing (Bonferroni), smaller grey
matter was conﬁrmed in FES subjects without cannabis
use vs. healthy control subjects, in the pedunculi, right
vermis, left ﬂocculus and right lobule III (Table 3).
There was neither an eﬀect of cannabis use (F1,51=0.02)
nor an interaction of cannabis use with the diagnosis
of schizophrenia on regional grey-matter diﬀerences
in the cerebellum (F1,51=0.84).
Discussion
To our knowledge, this is the ﬁrst study to link
cerebellar pathology to juvenile cannabis use by em-
ploying cortical pattern matching. We found small
dose-dependent regional eﬀects of cannabis use in the
cerebellum, resulting in reduced grey matter in the
right lobules III, IV, and V that also tends to be more
Table 2. Comparisons of total cerebellar volumes, total grey- and white-matter volumes, and grey : total cerebellar volume ratios
(standard deviations given in parentheses) for healthy control subjects, cannabis-using subjects, ﬁrst-episode schizophrenia
(FES) subjects, and cannabis-using FES subjects
Control
subjects
(n=19)
Cannabis-using
subjects (n=17) FES (n=13)
Cannabis
using FES
(n=6)
F
(d.f.=3,54) p
Total cerebellar volume (cc) 142.2 (13.1) 152.2 (13.9) 149.5 (10.5) 145.1 (7.4) 2.2 0.10
Total grey-matter volume (cc) 102.2 (10.0) 108.7 (9.7) 105.0 (7.3) 102.4 (5.4) 1.7 0.17
Total white-matter volume (cc) 40.0 (3.7) 43.5 (4.5) 44.4 (4.3) 42.7 (2.4) 3.8 <0.02*
Total grey : total cerebellar volume ratio 0.72 (0.01) 0.71 (0.01) 0.70 (0.02) 0.71 (0.01) 4.7 <0.01*
* Scheﬀe´’s post-hoc testing conﬁrms increased total white-matter volume (p=0.03) and decreased total grey : total cerebellar
volume ratio (p=0.007) in FES without cannabis use vs. control subjects.
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profound in lobule III with an earlier onset age of
cannabis use. Despite dose-dependent regional grey-
matter reduction in cannabis users, overall grey-
matter measures were within the normal range of
grey-matter variability for healthy subjects. By con-
trast, Medina et al. (2010) reported larger inferior pos-
terior vermis volumes in recently abstinent cannabis
users compared to a closely matched non-cannabis-
using cohort. Their volumetric approach, however,
does not discriminate between grey and white matter,
nor does it adjust for individual lobular morphology
when calculating group averages, thereby limiting the
comparability with the cortical pattern averaging
method of the current study. On the other hand, re-
mitted FES patients in the current study showed pro-
found regional grey-matter reduction in the vermis,
pedunculi, and right lobule III at an early stage of ill-
ness. The cerebellum was not atrophic in FES, in terms
of overall volume, but patients had greater total white-
matter volumes, resulting in smaller grey: total cer-
ebellar volume ratios suggestive of impaired brain
development (Harris et al. 1994).
Our ﬁndings conﬁrm cerebellar grey- and white-
matter pathology in schizophrenia (Andreasen &
(a) (b) (c) (d)
THC vs. Con FES vs. Con Diagnosis THC by FES
Fig. 2. From top to bottom, superior, left, right, posterior, anterior, and inferior views of cerebellum. (a) Parametric mapping
suggests no regional diﬀerences of cerebellar grey matter in cannabis users (THC) vs. pair-wise age-, gender-, and handedness-
matched healthy control subjects (Con). (b) By contrast, ﬁrst-episode schizophrenia (FES) subjects present with marked reduction
of grey matter in superior vermis ; in left lobule VI, in right-inferior lobule IX, extending into left lobule IX, bilaterally in the areas
of lobuli III, peduncle and left ﬂocculus compared to pair-wise age-, gender-, and handedness-matched healthy control subjects
(Con) (modiﬁed from Rasser et al. 2010). (c) A main eﬀect of the diagnosis of schizophrenia was conﬁrmed (d) due to grey-matter
loss on lobules III, IV, V, VI, IX, pedunculi, ﬂocculi, and vermis (light blue areas) which corresponds to the main eﬀect of
diagnosis of FES (two-way ANOVA of THC use by diagnosis of schizophrenia) in lobules III, IX, pedunculi, ﬂocculi, and vermis
(dark blue areas).
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Pierson, 2008 ; Picard et al. 2008). Moreover, these deﬁ-
cits are already detectable in the ﬁrst-episode phase of
the illness, following remission from acute psychosis.
These ﬁndings are also consistent with ﬁndings
from previous studies showing that the cerebellum
contributes to the clinical, cognitive, and patho-
physiological signs of the disorder.
For instance, vermal neuropathology has been re-
ported previously and also appears to be present in
neuroleptic-naive schizophrenia patients (Ichimiya
et al. 2001; Okugawa et al. 2007). Functionally, the
vermis is mainly involved in spinocerebellar proces-
sing of axial muscle coordination but has also been
linked to impaired attention control, dysregulation of
aﬀect, social dysfunction and delusions (Schmahmann
et al. 2008). This spectrum of psychopathology is
consistent with some of the positive (e.g. delusions,
inattention) and negative symptoms (e.g. ﬂat aﬀect,
social withdrawal) of schizophrenia. Other reports
found correlations of reduced vermal volume with
the depression and paranoia subscores of the Brief
Psychiatric Rating Scale (Ichimiya et al. 2001) and
greater vermis white-matter volumes with severity of
positive symptoms, thought disorder and impaired
verbal logical memory in patients with schizophrenia
(Levitt et al. 1999).
Table 3. Comparison of grey-matter proportion by lobule (standard deviations given in parentheses) in the (a) left and (b) right
cerebellar hemispheres for healthy control subjects, cannabis-using subjects, ﬁrst-episode schizophrenia (FES) subjects, and
cannabis-using FES subjects
Lobules
Control
subjects
(n=19)
Cannabis-using
subjects (n=17)
FES subjects
(n=13)
Cannabis-
using FES
subjects
(n=6)
F
(d.f.=3,54) p
(a) Left hemisphere
III 0.72 (0.04) 0.71 (0.04) 0.69 (0.04) 0.71 (0.02) 2.8 <0.05
IV 0.78 (0.04) 0.78 (0.04) 0.75 (0.04) 0.77 (0.03) 1.6 0.19
V 0.75 (0.03) 0.74 (0.03) 0.72 (0.03) 0.74 (0.03) 2.2 0.10
VI 0.75 (0.02) 0.75 (0.03) 0.73 (0.02) 0.74 (0.03) 2.3 0.09
Pedunculus 0.64 (0.03) 0.64 (0.03) 0.60 (0.02) 0.63 (0.03) 5.4 <0.01*
Crus I 0.79 (0.02) 0.79 (0.02) 0.78 (0.03) 0.78 (0.02) 0.5 0.68
Crus II 0.76 (0.02) 0.77 (0.02) 0.76 (0.02) 0.76 (0.01) 0.3 0.82
VIIB 0.76 (0.02) 0.76 (0.02) 0.75 (0.03) 0.76 (0.01) 0.2 0.91
VIIIA 0.76 (0.02) 0.76 (0.03) 0.75 (0.04) 0.76 (0.01) 0.4 0.73
VIIIB 0.77 (0.02) 0.77 (0.03) 0.75 (0.04) 0.76 (0.02) 1.0 0.40
IX 0.78 (0.02) 0.76 (0.03) 0.76 (0.03) 0.76 (0.04) 3.0 0.04
Vermis 0.80 (0.03) 0.78 (0.03) 0.76 (0.03) 0.77 (0.03) 3.2 0.03
Flocculus 0.66 (0.03) 0.66 (0.04) 0.63 (0.03) 0.63 (0.05) 3.3 0.03*
(b) Right hemisphere
III 0.73 (0.04) 0.72 (0.04) 0.69 (0.03) 0.69 (0.03) 4.4 <0.01*
IV 0.78 (0.03) 0.78 (0.04) 0.76 (0.03) 0.74 (0.04) 2.2 0.10
V 0.75 (0.03) 0.75 (0.03) 0.72 (0.03) 0.74 (0.03) 2.6 0.05
VI 0.75 (0.03) 0.75 (0.03) 0.73 (0.02) 0.73 (0.02) 2.0 0.13
Pedunculus 0.65 (0.03) 0.64 (0.04) 0.61 (0.02) 0.61 (0.03) 5.8 <0.01*
Crus I 0.79 (0.02) 0.79 (0.02) 0.79 (0.03) 0.77 (0.00) 0.8 0.49
Crus II 0.77 (0.02) 0.77 (0.01) 0.77 (0.02) 0.76 (0.01) 0.7 0.54
VIIB 0.76 (0.03) 0.76 (0.02) 0.75 (0.03) 0.75 (0.02) 0.2 0.92
VIIIA 0.77 (0.03) 0.77 (0.02) 0.76 (0.04) 0.78 (0.02) 0.9 0.44
VIIIB 0.78 (0.02) 0.77 (0.02) 0.76 (0.03) 0.78 (0.03) 1.6 0.20
IX 0.80 (0.02) 0.79 (0.02) 0.78 (0.03) 0.79 (0.01) 2.8 0.50
Vermis 0.80 (0.03) 0.79 (0.03) 0.77 (0.03) 0.77 (0.03) 3.9 0.01*
Flocculus 0.64 (0.03) 0.64 (0.03) 0.62 (0.02) 0.62 (0.06) 2.8 0.05
* Bonferroni-corrected p value. Scheﬀe´’s post-hoc testing conﬁrms smaller grey-matter proportions in FES without cannabis
use vs. healthy control subjects in left (p=0.008) and right (p=0.02) pedunculus, left (p=0.04) and right (p=0.03) vermis, and
right lobule III (p=0.02).
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Neuropathology of the cerebellar pedunculi is
also relevant to functional deﬁcits described in schizo-
phrenia, such as associative learning and the formation
of memory traces for the conditioned eye-blink re-
sponse (Thompson et al. 1997). Lower rates of eye-
blink conditioning, particularly less adaptively timed
conditioned response latencies, have been reported in
schizophrenia (Bolbecker et al. 2009). Our ﬁnding of
reduced grey matter in vermis and pedunculi suggests
cerebellar pathology that is already emerging follow-
ing the ﬁrst episode of illness.
There seems to be some overlap in regional grey-
matter pathology with cannabis use and FES in right
lobule III, but there was no conﬁrmation at group level
owing to the overall small eﬀects of cannabis use on
grey-matter pathology. This observation is consistent
with previous reports (Martı´n-Santos et al. 2010) and is
supported by our data from cannabis-using FES sub-
jects who do not show evidence of more profound
cerebellar neuropathology related to their cannabis
use. However, this observation must be regarded
as preliminary owing to the small sample size of
cannabis-using FES patients in our study.
On the other hand, according to a recent
meta-analysis (Stoodley & Schmahmann, 2009), subtle
grey-matter deﬁcits in right lobules III, IV, and V in
cannabis users may lead to somatosensory, language,
verbal working memory, spatial, and executive
function deﬁcits and may also aﬀect processing of
emotional information. Our ﬁndings of greater cer-
ebellar pathology with severity of cannabis-use history
suggest more pronounced deﬁcits in these functional
domains with an earlier onset of use and more accu-
mulated drug exposure. This interpretation is sup-
ported by meta-analytical data from a small number of
studies of cannabis users by Grant and colleagues
(2003). Cognitive deﬁcits are most likely to occur in the
domains of learning and memory, processing speed,
and selective attention (see also reviews by Cohen et al.
2008; Solowij & Battisti, 2008). The potential impact
on cognition of cannabis use requires further inves-
tigation.
Overall, our study is limited by sample size. This
reﬂects our diﬃculties of recruiting non-drug-using
FES patients and age-matched cannabis-using volun-
teers with no or very little abuse of other illicit drugs
or alcohol. Recruitment of solely cannabis-using FES
patients is most diﬃcult owing to the high levels
of multiple substance abuse in this population. On
the other hand, our data suggest that cortical pattern
matching overcomes some limitations of other
morphometric methods by accurately aligning group-
averaged cortical MRI data in relatively small cohorts,
thus providing the basis to map more accurately
potential brain functional deﬁcits onto in-vivo atlases
of brain pathology.
Note
Supplementary material accompanies this paper on
the Journal’s website (http ://journals.cambridge.org/
pnp).
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